跳至主要内容
临床试验/NCT01387698
NCT01387698已完成不适用

Observatoire Prospectif, Longitudinal Dans la Prise en Charge Thérapeutique de La Rectocolite Hémorragique légère à Modérée

Ferring Pharmaceuticals80 个研究点 分布在 1 个国家目标入组 812 人开始时间: 2011年6月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
812
试验地点
80
主要终点
Remission rate (ulcerative colitis) - calculated by UCCS (Ulcerative Colitis Clinical Score)

研究概览

简要总结

The primary objective of this study is to confirm the long-term efficacy (remission and maintenance in remission) of current validated treatments. Each patient will be followed during 3 years in this non-interventional trial.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years old or above
  • Ulcerative colitis, whatever the extension, in mild to moderate flare-up (including proctitis)
  • Having received the information sheet

排除标准

  • Participating, at the time of inclusion, in another study using an investigational drug or device

结局指标

主要结局

Remission rate (ulcerative colitis) - calculated by UCCS (Ulcerative Colitis Clinical Score)

时间窗: From baseline (inclusion visit) and at 3 year interval after baseline

次要结局

  • Colonoscopy (if available) - assessing endoscopic activity of the ulcerative colitis(From baseline (inclusion visit) to 3 year after baseline)
  • Occurence/number of adverse events(From baseline (inclusion visit) to year 3 after baseline)
  • Assessing treatment adherence by patient's completion of questionnaire MMAS-8 (Modified Morisky Adherence Scale)(From baseline (inclusion visit) and at 3 year interval after baseline)
  • Remission rate (endoscopic) - calculated by UC-DAI (Ulcerative Colitis Disease Activity Index)(From baseline (inclusion visit) and at 3 year interval after baseline)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (80)

Loading locations...

相似试验